Premium
P2–389: Intravenous pulse cyclophosphamide in Alzheimer's disease: Results of a pilot dose–finding study
Author(s) -
Gordon Marc L.,
Mirza Nadeem,
Bauer Larry,
Spoor Eleanor,
Overman Gerald,
Dustin Irene,
Fleischer Thomas A.,
Putnam Karen,
Cohen Robert M.,
Sunderland Trey
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.1228
Subject(s) - medicine , tolerability , placebo , randomized controlled trial , adverse effect , cyclophosphamide , gastroenterology , chemotherapy , pathology , alternative medicine
0.7(MDD), 2.8 /0.4(D), with a mean improvement observed at Week 4 of -0.1 /0.4(MDD), -0.3 /0.6(D). The mean change in Likert score for anxiety symptoms at Week 4 -0.1 /0.3(MDD), -0.2 /0.6(D). Mean change in Likert score for depressive symptoms at Week 4 -0.1 /0.3(MDD), -0.1 /0.5(D). No change in Likert score for psychotic symptoms in the MDD group was observed, however the mean change at Week 4 -0.2 /0.5(D). On a Visual Analogue Scale for acceptability of treatment, both diagnostic groups favorably rated orally disintegrating risperidone tablets, with patients rating acceptability at 6.4/10(MDD) and 7/10(D) respectively. The most frequent AE reported was headache. Conclusions: Orally disintegrating risperidone tablets offer an alternative, well-tolerated method of drug delivery with no evidence of symptom decompensation when transitioned from the previous risperidone formulation.